Download DNB 2020 June Medical Oncology Paper I Question Paper

Download Diplomate of National Board (DNB) 2020 June Medical Oncology Paper I Question Paper

FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
MEDICAL ONCOLOGY
PAPER-I
Time: 3 hours
MED.ONCO./J/20/17/I
Max. Marks:100
Important Instructions:
Attempt all questions in order.
Each question carries 10 marks.
Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. a) Goldie-Coldman hypothesis.
2+4+4
b) Dose density in chemotherapy.
c) Chemo-radiation.
2. a) Clinical application of pharmacogenomics.
3+4+3
b) Potential applications of Artificial Intel igence in Oncology.
c) Phase 0 clinical trials.
3. a) Clinical applications of massive paral el sequencing.
3+4+3
b) Testing for KRAS mutations in Oncology.
c) Epigenetics in cancer.
4. a) Enumerate polyposis syndromes with risk of colon cancer.
2+4+4
b) Microsatel ite instability.
c) Immunotherapy of colon cancer.
5. a) Tumour mutation burden.
2+4+4
b) PERCIST 1.0.
c) Imaging of Neuro-endocrine tumours.
6. a) Targeted agents as radio-sensitizers.
3+3+4
b) Antibody-drug conjugates.
c) Enumerate various approaches of immunotherapy with examples.
7. a) Sunscreens in prevention of skin cancer.
3+4+3
b) Assessment of risk for hereditary breast cancer.
c) Hormonal prevention of breast cancer.
8. a) Ebstein-Barr virus and human cancer.
4+3+3
b) Hepatitis C and cancer.
c) Vaccines in prevention of cancers due to infections.
P.T.O
-1-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

---

FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
MEDICAL ONCOLOGY
PAPER-I
9. a) Targeted therapies that inhibit VEGF signaling.
4+3+3
b) Adverse effects of VEGF inhibitors.
c) Newer VEGF molecules available for therapy.
10. a) Imaging studies in diagnosis and staging of ovarian cancer.
4+3+3
b) Role of interim PET-CT scan in DLBCL treatment.
c) Tomosynthesis.
************
-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

---